CYCC
Income statement / Annual
Last year (2025), Cyclacel Pharmac's total revenue was $747.00 K,
an increase of 1,637.21% from the previous year.
In 2025, Cyclacel Pharmac's net income was -$3.00 M.
See Cyclacel Pharmac,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$747.00 K |
$43.00 K |
$420.00 K |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$150.00 K |
$0.00 |
$843.00 K |
| Cost of Revenue |
$609.00 K
|
$0.00
|
$0.00
|
$32.00 K
|
$43.00 K
|
$20.00 K
|
$0.00
|
$4.33 M
|
$32.00 K
|
$9.48 M
|
| Gross Profit |
$138.00 K
|
$43.00 K
|
$420.00 K
|
-$32.00 K
|
-$43.00 K
|
-$20.00 K
|
-$20.00 K
|
-$4.18 M
|
-$32.00 K
|
-$8.63 M
|
| Gross Profit Ratio |
0.18
|
1
|
1
|
0
|
0
|
0
|
0
|
-27.85
|
0
|
-10.24
|
| Research and Development Expenses |
$848.00 K
|
$6.66 M
|
$19.16 M
|
$20.27 M
|
$14.93 M
|
$4.76 M
|
$4.66 M
|
$4.33 M
|
$4.24 M
|
$9.48 M
|
| General & Administrative Expenses |
$7.72 M
|
$5.39 M
|
$6.72 M
|
$7.38 M
|
$7.46 M
|
$5.88 M
|
$5.02 M
|
$5.37 M
|
$5.25 M
|
$5.52 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$7.72 M
|
$5.39 M
|
$6.72 M
|
$7.38 M
|
$7.46 M
|
$5.88 M
|
$5.02 M
|
$5.37 M
|
$5.25 M
|
$5.52 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$8.57 M
|
$12.05 M
|
$25.87 M
|
$27.66 M
|
$22.39 M
|
$10.64 M
|
$9.68 M
|
$9.70 M
|
$9.49 M
|
$14.99 M
|
| Cost And Expenses |
$9.17 M
|
$12.05 M
|
$25.87 M
|
$27.66 M
|
$22.39 M
|
$10.64 M
|
$9.68 M
|
$9.70 M
|
$9.49 M
|
$14.99 M
|
| Interest Income |
$62.00 K
|
$12.00 K
|
$266.00 K
|
$210.00 K
|
$16.00 K
|
$42.00 K
|
$224.00 K
|
$331.00 K
|
$118.00 K
|
$37.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$6.00 K
|
$31.00 K
|
$32.00 K
|
$43.00 K
|
$20.00 K
|
$20.00 K
|
$29.00 K
|
$32.00 K
|
$133.00 K
|
| EBITDA |
-$8.43 M |
-$12.00 M |
-$25.42 M |
-$27.62 M |
-$22.69 M |
-$10.62 M |
-$9.66 M |
-$9.52 M |
-$9.46 M |
-$14.02 M |
| EBITDA Ratio |
-11.28
|
-279.02
|
-60.53
|
0
|
0
|
0
|
0
|
-63.46
|
0
|
-16.63
|
| Operating Income Ratio |
-11.28
|
-279.16
|
-60.6
|
0
|
0
|
0
|
0
|
-63.65
|
0
|
-16.79
|
| Total Other Income/Expenses Net |
$5.42 M
|
$10.00 K
|
-$98.00 K
|
$1.74 M
|
$204.00 K
|
$955.00 K
|
$556.00 K
|
$923.00 K
|
$1.03 M
|
$376.00 K
|
| Income Before Tax |
-$3.01 M
|
-$11.99 M
|
-$25.55 M
|
-$25.92 M
|
-$22.19 M
|
-$9.68 M
|
-$9.13 M
|
-$8.63 M
|
-$8.46 M
|
-$13.77 M
|
| Income Before Tax Ratio |
-4.02
|
-278.93
|
-60.84
|
0
|
0
|
0
|
0
|
-57.5
|
0
|
-16.34
|
| Income Tax Expense |
-$7.00 K
|
-$782.00 K
|
-$3.00 M
|
-$4.72 M
|
-$3.85 M
|
-$1.24 M
|
-$1.30 M
|
-$1.34 M
|
-$993.00 K
|
-$1.98 M
|
| Net Income |
-$3.00 M
|
-$11.21 M
|
-$22.56 M
|
-$21.20 M
|
-$18.89 M
|
-$8.45 M
|
-$7.83 M
|
-$7.29 M
|
-$7.47 M
|
-$11.79 M
|
| Net Income Ratio |
-4.01
|
-260.74
|
-53.7
|
0
|
0
|
0
|
0
|
-48.59
|
0
|
-13.99
|
| EPS |
-6.45 |
-1.36 |
-28.67 |
-28.5 |
-32.1 |
-12.73 |
-9.64 |
-12.462 |
-18.70238 |
-70.35 |
| EPS Diluted |
-6.45 |
-1.36 |
-28.67 |
-28.5 |
-32.1 |
-12.73 |
-9.64 |
-12.462 |
-18.70238 |
-70.35 |
| Weighted Average Shares Out |
$2.19 M
|
$8.31 M
|
$797.63 K
|
$750.38 K
|
$595.07 K
|
$666.63 K
|
$816.08 K
|
$604.70 K
|
$401.40 K
|
$171.24 K
|
| Weighted Average Shares Out Diluted |
$2.19 M
|
$8.31 M
|
$797.63 K
|
$750.38 K
|
$595.07 K
|
$666.63 K
|
$816.08 K
|
$604.70 K
|
$401.40 K
|
$171.24 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
